Laval, Québec, CANADA – June 7, 2012 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.NTB) announces that the U.S. Patent & Trademark Office (the “USPTO”) has allowed one of its continuation patent applications, number 13/189,714, which claims the benefit of Neptune’s U.S. Patent No. 8,030,348 (“the ‘348 Patent”). This continuation application contains claims to further embodiments of the inventions that were disclosed in the ‘348 Patent; specifically to krill extracts comprising a phospholipid suitable for human consumption. These claims cover a number of krill oil products presently sold in the U.S. market.

The continuation application, which was filed less than a year ago, was allowed by the USPTO after a thorough examination. During prosecution, Neptune provided the USPTO with a substantial volume of prior art references and other materials, including the papers from re-examination requests filed by Aker Biomarine ASA (“Aker”) directed to the ‘348 Patent and a related Neptune patent, and the oppositions being undertaken on related Neptune patents in Europe and Australia.

Henri Harland, President and CEO of Neptune, stated: “The fact that the USPTO has allowed this continuation of the ‘348 Patent, after considering the prior art and evidence submitted by Aker in the re-examination of the ‘348 Patent, is for us, a clear indication of the strength of the continuation claims. This new patent will reinforce our positioning and further confirm our pioneering role in the krill oil industry. We expect our competitors to again downplay the importance of this achievement for Neptune, but the fact remains that we are continuously building our IP and market positioning, not only in the United States, but also throughout the world. We intend to fully enforce our patents against anyone who infringes.”

About Acasti Pharma Inc.
Acasti Pharma (TSXV: APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm Inc.